Cibus (NASDAQ:CBUS – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Cibus to related companies based on the strength of its risk, earnings, valuation, profitability, dividends, analyst recommendations and institutional ownership.
Insider and Institutional Ownership
33.8% of Cibus shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 29.9% of Cibus shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk & Volatility
Cibus has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Cibus’ competitors have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Cibus and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cibus | 1 | 1 | 1 | 0 | 2.00 |
| Cibus Competitors | 9919 | 15313 | 45656 | 1602 | 2.54 |
Cibus presently has a consensus target price of $9.00, suggesting a potential upside of 696.46%. As a group, “Biotechnology” companies have a potential upside of 126.38%. Given Cibus’ higher possible upside, analysts plainly believe Cibus is more favorable than its competitors.
Profitability
This table compares Cibus and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cibus | -2,131.38% | -526.66% | -28.12% |
| Cibus Competitors | -12,224.09% | -202.33% | -31.23% |
Earnings & Valuation
This table compares Cibus and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Cibus | $3.64 million | -$127.08 million | -0.75 |
| Cibus Competitors | $727.18 million | $10.07 million | -18.81 |
Cibus’ competitors have higher revenue and earnings than Cibus. Cibus is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Summary
Cibus competitors beat Cibus on 7 of the 13 factors compared.
About Cibus
Cibus is an agricultural technology company that develops plant traits using gene-editing technologies. Its proprietary Rapid Trait Development System (RTDS) is designed to make precise changes to a plant’s own genes, with the goal of developing useful crop characteristics without adding foreign DNA. The company’s research and development focuses on traits for crops including canola, rice and wheat, such as herbicide tolerance and resistance to crop diseases. Cibus aims to bring these traits to market through seed and technology licensing arrangements with partners in the agricultural industry.
Receive News & Ratings for Cibus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus and related companies with MarketBeat.com's FREE daily email newsletter.
